Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 100,581 shares at $0.69 ($64K) on 2026-05-05, disclosed to the SEC on 2026-05-07.
Scheduled sale ($64k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.69 | 6,860 | $5K | 7.4% |
| 2 | $0.66 | 14,635 | $10K | 15.0% |
| 3 | $0.63 | 79,086 | $50K | 77.6% |
| Total | $0.64 avg | 100,581 | $64K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |